Abstract
BackgroundPatients with adult-onset Still's disease (AOSD) experience frequent relapses. Several case series and cohort studies showed the relatively short-term effectiveness of tocilizumab (TCZ), an anti-interleukin-6 receptor monoclonal antibody, on the...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have